{"id":"W2171367970","doi":"10.1200/jco.2012.44.7888","title":"Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":363,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Jonsson Comprehensive Cancer Center; University of Texas MD Anderson Cancer Center; University of California, Los Angeles; Peter MacCallum Cancer Centre; Plexxikon; Vanderbilt University; Moffitt Cancer Center; Genentech; University of Pittsburgh; F. Hoffmann-La Roche; Vanderbilt-Ingram Cancer Center; York University; University of Pennsylvania; Massachusetts General Hospital; GlaxoSmithKline","keywords":"Vemurafenib; Medicine; Neuroblastoma RAS viral oncogene homolog; MAPK/ERK pathway; Cancer research; Melanoma; Kinase; Phosphorylation; Internal medicine; Cancer; Metastatic melanoma; KRAS; Biology; Colorectal cancer; Cell biology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01935879750345848,"score_gpt":0.3406378477840598,"score_spread":0.3212790502806013,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}